Skip to main content

Advertisement

SpringerLink
Log in

The cardioprotective effects of statins

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

In addition to their lipid-modulating properties, statins have a large number of beneficial cardiovascular effects that have emerged over time and that were not anticipated during drug development. The lipid and nonlipid effects act in a concerted way to reduce the ischemic burden of the myocardium and to protect it against injury. By acting on the vessel wall, statins may prevent lesion initiation and repair injuries, enhance myocardial perfusion, slow lesion progression, and prevent coronary occlusion. They may also directly reduce myocardial damage, favor myocardial repair, and protect against immune injury. This review focuses on properties of statins that contribute to their cardioprotective effect. The first section includes information on modulation of vascular tone, endothelial permeability and function, inhibition of complement injury, curbing of foam cell formation, antioxidant and anti-inflammatory properties, and profibrinolytic and anticoagulant activities. The second section relates to reduction of myocardial necrosis, myocardial hypertrophy, blood pressure, and heart failure, as well as mobilization of endothelial progenitor cells for repair, angiogenic effects, and immunomodulation. In many instances, results of in vitro and animal studies have raised expectations and prompted studies in humans. Several clinical trials have confirmed these expectations and have strengthened the value of statins as valuable antiatherosclerotic and cardioprotective agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Davignon J, Laaksonen R: Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999, 10:543–559.

    Article  PubMed  CAS  Google Scholar 

  2. Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002, 110:285–288.

    Article  PubMed  CAS  Google Scholar 

  3. Laufs U: Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003, 58:719–731.

    PubMed  CAS  Google Scholar 

  4. Bonetti PO, Lerman LO, Lerman A: Endothelial dysfunction—a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003, 23:168–175.

    Article  PubMed  CAS  Google Scholar 

  5. Laufs U, Wassmann S, Hilgers S, et al.: Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Am J Cardiol 2001, 88:1306–1307.

    Article  PubMed  CAS  Google Scholar 

  6. Dalla Nora E, Passaro A, Zamboni PF, et al.: Atorvastatin improves metabolic control and endothelial function in Type 2 diabetic patients: a placebo-controlled study. J Endocrinol Invest 2003, 26:73–78.

    Google Scholar 

  7. Olsson AG, Schwartz GG: Early initiation of treatment with statins in acute coronary syndromes. Ann Med 2002, 34:37–41.

    Article  PubMed  CAS  Google Scholar 

  8. Delbosc S, Morena M, Djouad F, et al.: Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol 2002, 40:611–617.

    Article  PubMed  CAS  Google Scholar 

  9. Wassmann S, Laufs U, Bäumer AT, et al.: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001, 37:1450–1457.

    PubMed  CAS  Google Scholar 

  10. Nègre-Aminou P, Van Leeuwen RE, Van Thiel GC, et al.: Differential effect of simvastatin on activation of Rac1 vs. activation of the heat shock protein 27-mediated pathway upon oxidative stress, in human smooth muscle cells. Biochem Pharmacol 2002, 64:1483–1491.

    Article  PubMed  Google Scholar 

  11. Chenevard R, Hürlimann D, Béchir M, et al.: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003, 107:405–409.

    Article  PubMed  Google Scholar 

  12. Hernández-Presa MA, Martín-Ventura JL, Ortego M, et al.: Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002, 160:49–58.

    Article  PubMed  Google Scholar 

  13. Dell’Omo G, Bandinelli S, Penno G, Pedrinelli R, Mariani M: Simvastatin, capillary permeability, and acetylcholine-mediated vasomotion in atherosclerotic, hypercholesterolemic men. Clin Pharmacol Ther 2000, 68:427–434.

    Article  PubMed  CAS  Google Scholar 

  14. Mason JC, Ahmed Z, Mankoff R, et al.: Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 2002, 91:696–703.

    Article  PubMed  CAS  Google Scholar 

  15. Urbich C, Dernbach E, Zeiher AM, Dimmeler S: Double-edged role of statins in angiogenesis signaling. Circ Res 2002, 90:737–744.

    Article  PubMed  CAS  Google Scholar 

  16. Glorioso N, Troffa C, Filigheddu F, et al.: Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34:1281–1286.

    PubMed  CAS  Google Scholar 

  17. Nakamura T, Ushiyama C, Hirokawa K, et al.: Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 2001, 21:449–454.

    Article  PubMed  CAS  Google Scholar 

  18. Lowe G, Rumley A, Norrie J, et al.: Blood rheology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland Coronary Prevention Study. Thromb Haemost 2000, 84:553–558.

    PubMed  CAS  Google Scholar 

  19. Kohno M, Murakawa K, Yasunari K, et al.: Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients. Metabolism 1997, 46:287–291.

    Article  PubMed  CAS  Google Scholar 

  20. Koh KK: Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol 2000, 76:23–32.

    Article  PubMed  CAS  Google Scholar 

  21. Giroux LM, Davignon J, Naruszewicz M: Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta Lipids Lipid Metab 1993, 1165:335–338.

    Article  CAS  Google Scholar 

  22. Umetani N, Kanayama Y, Okamura M, et al.: Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages. Biochim Biophys Acta Lipids Lipid Metab 1996, 1303:199–206.

    Article  Google Scholar 

  23. Pietsch A, Erl W, Lorenz RL: Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol 1996, 52:433–439.

    Article  PubMed  CAS  Google Scholar 

  24. Draude G, Hrboticky N, Lorenz RL: The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem Pharmacol 1999, 57:383–386.

    Article  PubMed  CAS  Google Scholar 

  25. Fuhrman B, Koren L, Volkova N, et al.: Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 2002, 164:179–185.

    Article  PubMed  CAS  Google Scholar 

  26. Li DY, Singh RM, Liu L, et al.: Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells. Cardiovasc Res 2003, 57:238–243.

    Article  PubMed  CAS  Google Scholar 

  27. Li DY, Liu L, Chen HJ, et al.: LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003, 107:612–617.

    Article  PubMed  CAS  Google Scholar 

  28. Li DY, Liu L, Chen HJ, et al.: LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol 2003, 23:816–821.

    Article  PubMed  CAS  Google Scholar 

  29. Li DY, Chen HJ, Mehta JL: Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 2001, 52:130–135.

    Article  PubMed  CAS  Google Scholar 

  30. Corti R, Fuster V, Fayad ZA, et al.: Lipid lowering by simvastatin induces regression of human atherosclerotic lesions—two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002, 106:2884–2887.

    Article  PubMed  CAS  Google Scholar 

  31. Crisby M, Nordin-Fredriksson G, Shah PK, et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques—implications for plaque stabilization. Circulation 2001, 103:926–933.

    PubMed  CAS  Google Scholar 

  32. Aikawa M, Rabkin E, Sugiyama S, et al.: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001, 103:276–283.

    PubMed  CAS  Google Scholar 

  33. Kwak BR, Veillard N, Pelli G, et al.: Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation 2003, 107:1033–1039.

    Article  PubMed  CAS  Google Scholar 

  34. Luan ZX, Chase AJ, Newby AC: Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003, 23:769–775.

    Article  PubMed  CAS  Google Scholar 

  35. Cipollone F, Fazia M, Iezzi A, et al.: Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003, 107:I479-I485.

    Google Scholar 

  36. Jialal I, Stein D, Balis D, et al.: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001, 103:1933–1935.

    PubMed  CAS  Google Scholar 

  37. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001, 7:687–692.

    Article  PubMed  CAS  Google Scholar 

  38. Weitz-Schmidt G: Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002, 23:482–486.

    Article  PubMed  CAS  Google Scholar 

  39. Stefanadis C, Toutouzas K, Vavuranakis M, et al.: Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques. Eur Heart J 2002, 23:1664–1669.

    PubMed  CAS  Google Scholar 

  40. Ehara S, Ueda M, Naruko T, et al.: Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001, 103:1955–1960.

    PubMed  CAS  Google Scholar 

  41. Hulthe J, Fagerberg B: Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Arterioscler Thromb Vasc Biol 2002, 22:1162–1167.

    Article  PubMed  CAS  Google Scholar 

  42. Nishi K, Itabe H, Uno M, et al.: Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002, 22:1649–1654.

    Article  PubMed  CAS  Google Scholar 

  43. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129–1135.

    PubMed  CAS  Google Scholar 

  44. Heitzer T, Ylä-Herttuala S, Luoma J, et al.: Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia—role of oxidized LDL. Circulation 1996, 93:1346–1353.

    PubMed  CAS  Google Scholar 

  45. Miyazaki H, Matsuoka H, Itabe H, et al.: Hemodialysis impairs endothelial function via oxidative stress—Effects of vitamin E-coated dialyzer. Circulation 2000, 101:1002–1006.

    PubMed  CAS  Google Scholar 

  46. Sánchez-Quesada JL, Otal-Entraigas C, Franco M, et al.: Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 1999, 84:655–659.

    Article  PubMed  Google Scholar 

  47. Shishehbor MH, Aviles RJ, Brennan ML, et al.: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003, 289:1675–1680.

    Article  PubMed  CAS  Google Scholar 

  48. Eto M, Luscher TF: Modulation of coagulation and fibrinolytic pathways by statins. Endothelium 2003, 10:35–41.

    Article  PubMed  CAS  Google Scholar 

  49. Di Garbo V, Bono M, Di Raimondo D, et al.: Nonlipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response. Eur J Clin Pharmacol 2000, 56:277–284.

    Article  PubMed  Google Scholar 

  50. Seljeflot I, Tonstad S, Hjermann I, Arnesen H: Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 2002, 105:285–290.

    Article  PubMed  CAS  Google Scholar 

  51. Son JW, Koh KK, Ahn JY, et al.: Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease. Int J Cardiol 2003, 88:77–82.

    Article  PubMed  Google Scholar 

  52. Hölschermann H, Hilgendorff A, Kemkes-Matthes B, et al.: Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation 2000, 69:1830–1836.

    Article  PubMed  Google Scholar 

  53. Masamura K, Oida K, Kanehara H, et al.: Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 2003, 23:512–517.

    Article  PubMed  CAS  Google Scholar 

  54. Heeschen C, Dimmeler S, Hamm CW, et al.: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348:1104–1111.

    Article  PubMed  CAS  Google Scholar 

  55. Cipollone F, Mezzetti A, Porreca E, et al.: Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia effects of statin therapy. Circulation 2002, 106:399–402.

    Article  PubMed  CAS  Google Scholar 

  56. Semb AG, Van Wissen S, Ueland T, et al.: Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: Downregulatory effect of statin therapy. J Am Coll Cardiol 2003, 41:275–279.

    Article  PubMed  CAS  Google Scholar 

  57. Schönbeck U, Gerdes N, Varo N, et al.: Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002, 106:2888–2893.

    Article  PubMed  CAS  Google Scholar 

  58. Wagner AH, Gebauer M, Güldenzoph B, Hecker M: 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 2002, 22:1784–1789.

    Article  PubMed  CAS  Google Scholar 

  59. Cortellaro M, Cofrancesco E, Arbustini E, et al.: Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study. Thromb Haemost 2002, 88:41–47.

    PubMed  CAS  Google Scholar 

  60. Wolfrum S, Grimm M, Heidbreder M, et al.: Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase. J Cardiovasc Pharmacol 2003, 41:474–480.

    Article  PubMed  CAS  Google Scholar 

  61. Bell RM, Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003, 41:508–515.

    Article  PubMed  CAS  Google Scholar 

  62. Ikeda Y, Young LH, Lefer AM: Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 2003, 41:649–656.

    Article  PubMed  CAS  Google Scholar 

  63. Heeschen C, Hamm CW, Laufs U, et al.: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446–1452.

    Article  PubMed  CAS  Google Scholar 

  64. Heeschen C, Hamm CW, Laufs U, et al.: Withdrawal of statins in patients with acute coronary syndromes. Circulation 2003, 107:E27.

    Google Scholar 

  65. Aronow HD, Quinn MJ, Topol EJ, et al.: Myocardial necrosis is halved in patients undergoing elective percutaneous coronary intervention who are pretreated with lipid-lowering therapy [abstract]. J Am Coll Cardiol 2002, 39:32A.

    Google Scholar 

  66. Herrmann J, Lerman A, Baumgart D, et al.: Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002, 106:2180–2183.

    Article  PubMed  CAS  Google Scholar 

  67. Walter DH, Fichtlscherer S, Britten MB, et al.: Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction. Am J Cardiol 2002, 89:1–6.

    Article  PubMed  CAS  Google Scholar 

  68. Chan AW, Bhatt DL, Chew DP, et al.: Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003, 107:1750–1756.

    Article  PubMed  CAS  Google Scholar 

  69. Bunch TJ, Muhlestein JB, Anderson JL, et al.: Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment. Am J Cardiol 2002, 90:299–302.

    Article  PubMed  CAS  Google Scholar 

  70. Schömig A, Mehilli J, Holle H, et al.: Statin treatment following coronary artery stenting and one-year survival. J Am Coll Cardiol 2002, 40:854–861.

    Article  PubMed  Google Scholar 

  71. Poldermans D, Bax JJ, Kertai MD, et al.: Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003, 107:1848–1851.

    Article  PubMed  CAS  Google Scholar 

  72. Pelat M, Dessy C, Massion P, et al.: Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003, 107:2480–2486.

    Article  PubMed  CAS  Google Scholar 

  73. Straznicky NE, Howes LG, Lam W, Louis WJ: Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995, 75:582–586.

    Article  PubMed  CAS  Google Scholar 

  74. Abetel G, Poget PN, Bonnabry JP: Antihypertensive effect of a cholesterol-lowering agent (fluvastatin). Pilot study. Schweiz Med Wochenschr 1998, 128:272–277.

    PubMed  CAS  Google Scholar 

  75. Borghi C, Prandin MG, Costa FV, et al.: Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000, 35:549–555.

    Article  PubMed  CAS  Google Scholar 

  76. Prasad GV, Ahmed A, Nash MM, Zaltzman JS: Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int 2003, 63:360–364.

    Article  PubMed  CAS  Google Scholar 

  77. Hayashidani S, Tsutsui H, Shiomi T, et al.: Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 105:868–873.

    Article  PubMed  CAS  Google Scholar 

  78. Pliquett RU, Cornish KG, Peuler JD, Zucker IH: Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003, 107:2493–2498.

    Article  PubMed  CAS  Google Scholar 

  79. Aronow WS, Ahn C: Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol greater than or equal to 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002, 90:147–149.

    Article  PubMed  CAS  Google Scholar 

  80. Kjekshus J, Pedersen TR, Olsson AG, et al.: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997, 3:249–254.

    Article  PubMed  CAS  Google Scholar 

  81. Anker S, Sharma R, Francis D, et al.: Statins and chronic heart failure: data from ELITE-II. Eur Heart J 2003, 24:362.

    Article  Google Scholar 

  82. Node K, Fujita M, Kitakaze M, et al.: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108:839–843.

    Article  PubMed  CAS  Google Scholar 

  83. Laufs U, Kilter H, Konkol C, et al.: Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002, 53:911–920.

    Article  PubMed  CAS  Google Scholar 

  84. Takemoto M, Node K, Nakagami H, et al.: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001, 108:1429–1437.

    Article  PubMed  CAS  Google Scholar 

  85. Lee TM, Chou TF, Tsai CH: Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin F2a formation. J Cardiovasc Pharmacol 2002, 40:868–874.

    Article  PubMed  CAS  Google Scholar 

  86. Bellamy MF, Pellikka PA, Klarich KW, et al.: Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002, 40:1723–1730.

    Article  PubMed  CAS  Google Scholar 

  87. Novaro GM, Tiong IY, Pearce GL, et al.: Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001, 104:2205–2209.

    PubMed  CAS  Google Scholar 

  88. Young-Xu Y: Statins reduce the incidence of auricular fibrillation in coronary artery disease [abstract]. J Am Coll Cardiol 2003, 41:301A.

  89. Orlic D, Kajstura J, Chimenti S, et al.: Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001, 98:10344–10349.

    Article  PubMed  CAS  Google Scholar 

  90. Strauer BE, Brehm M, Zeus T, et al.: Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002, 106:1913–1918.

    Article  PubMed  Google Scholar 

  91. Dimmeler S, Aicher A, Vasa M, et al.: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001, 108:391–397.

    Article  PubMed  CAS  Google Scholar 

  92. Vasa M, Fichtlscherer S, Adler K, et al.: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001, 103:2885–2890.

    PubMed  CAS  Google Scholar 

  93. Assmus B, Urbich C, Aicher A, et al.: HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003, 92:1049–1055.

    Article  PubMed  CAS  Google Scholar 

  94. Kureishi Y, Luo ZY, Shiojima I, et al.: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000, 6:1004–1010.

    Article  PubMed  CAS  Google Scholar 

  95. Skaletz-Rorowski A, Lutchman M, Kureishi Y, et al.: HMG-CoA reductase inhibitors promote cholesterol-dependent Akt/PKB translocation to membrane domains in endothelial cells. Cardiovasc Res 2003, 57:253–264.

    Article  PubMed  CAS  Google Scholar 

  96. Wilson SH, Herrmann J, Lerman LO, et al.: Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002, 105:415–418.

    Article  PubMed  CAS  Google Scholar 

  97. Sata M, Nishimatsu H, Suzuki E, et al.: Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J 2001, 15:NIL20-NIL33.

    Google Scholar 

  98. Weis M, Heeschen C, Glassford AJ, Cooke JP: Statins have biphasic effects on angiogenesis. Circulation 2002, 105:739–745.

    Article  PubMed  CAS  Google Scholar 

  99. Feleszko W, Balkowiec EZ, Sieberth E, et al.: Lovastatin and tumor necrosis factor-a exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 1999, 81:560–567.

    Article  PubMed  CAS  Google Scholar 

  100. Alber HF, Dulak J, Frick M, et al.: Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol 2002, 39:1951–1955.

    Article  PubMed  CAS  Google Scholar 

  101. Blann AD, Belgore FM, Constans J, et al.: Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001, 87:1160–1163.

    Article  PubMed  CAS  Google Scholar 

  102. St Croix B, Rago C, Velculescu V, et al.: Genes expressed in human tumor endothelium. Science 2000, 289:1197–1202.

    Article  PubMed  CAS  Google Scholar 

  103. Kwak B, Mulhaupt F, Myit S, Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399–1402.

    Article  PubMed  CAS  Google Scholar 

  104. Youssef S, Stüve O, Patarroyo JC, et al.: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78–84.

    Article  PubMed  CAS  Google Scholar 

  105. Naoumova RP, Patel DD, O’Neill FH, et al.: Treatment with atorvastatin alters interleukin-12 and-10 gene expression. Eur J Clin Invest 2003, 33:88–91.

    Article  PubMed  CAS  Google Scholar 

  106. Wenke K, Meiser B, Thiery J, et al.: Simvastatin initiated early after heart transplantation—8-year prospective experience. Circulation 2003, 107:93–97.

    Article  PubMed  CAS  Google Scholar 

  107. Shovman O, Levy Y, Gilburd B, Shoenfeld Y: Antiinflammatory and immunomodulatory properties of statins. Immunol Res 2002, 25:271–285.

    Article  PubMed  CAS  Google Scholar 

  108. Leung BP, Sattar N, Crilly A, et al.: A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003, 170:1524–1530.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal (IRCM), 110 Pine Avenue West, H2W 1R7, Montreal, QC, Canada

    Jean Davignon MD, MSc

Authors
  1. Jean Davignon MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davignon, J. The cardioprotective effects of statins. Curr Atheroscler Rep 6, 27–35 (2004). https://doi.org/10.1007/s11883-004-0113-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-004-0113-7

Keywords

Search

Navigation